Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of Novel Bromophenol–Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer
Chuanlong Guo, Lijun Wang, Xiuxue Li, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 6, pp. 3051-3067
Closed Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

1,2,3‐Triazole hybrids as anticancer agents: A review
Mohammad Mahboob Alam
Archiv der Pharmazie (2021) Vol. 355, Iss. 1
Closed Access | Times Cited: 216
Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer
Ana Podolski-Renić, Ana Čipak Gašparović, Andreia Valente, et al.
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116363-116363
Closed Access | Times Cited: 23
Advances of antitumor drug discovery in traditional Chinese medicine and natural active products by using multi‐active components combination
Wei Zhao, Xiao‐Di Zheng, Paula Yun‐Zhi Tang, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1778-1808
Closed Access | Times Cited: 40
Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship
Pronoy Kanti Das, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, et al.
European Journal of Medicinal Chemistry (2024) Vol. 274, pp. 116535-116535
Closed Access | Times Cited: 12
Designing an anticancer Pd(II) complex as poly(ADP-ribose) polymerase 1 inhibitor
Shuangshuang Gai, Peng Cao, Xuwei Zhong, et al.
International Journal of Biological Macromolecules (2025) Vol. 297, pp. 139885-139885
Closed Access | Times Cited: 1
Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer
Tingting Liu, Shubin Song, Xu Wang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112954-112954
Closed Access | Times Cited: 59
Design, synthesis, biological activity, molecular docking and computational studies on novel 1,4-disubstituted-1,2,3-Triazole-Thiosemicarbazone hybrid molecules
Naveen Naveen, Ram Kumar Tittal, Vikas D. Ghule, et al.
Journal of Molecular Structure (2020) Vol. 1209, pp. 127951-127951
Closed Access | Times Cited: 56
Evaluation of inhibitory effects of some novel phenolic derivatives on the mushroom tyrosinase activity: Insights from spectroscopic analyses, molecular docking and in vitro assays
Atiyeh Mahdavi, Nahid Mohammadsadeghi, F. Mohammadi, et al.
Food Chemistry (2022) Vol. 387, pp. 132938-132938
Closed Access | Times Cited: 33
Designing Tailored Thiosemicarbazones with Bespoke Properties: The Styrene Moiety Imparts Potent Activity, Inhibits Heme Center Oxidation, and Results in a Novel “Stealth Zinc(II) Complex”
Mahendiran Dharmasivam, Büşra Kaya, Tharushi P. Wijesinghe, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 2, pp. 1426-1453
Closed Access | Times Cited: 20
Synthesis and anticancer mechanisms of zinc(ii)-8-hydroxyquinoline complexes with 1,10-phenanthroline ancillary ligands
Ling-Qi Du, Tianyu Zhang, Xiaomei Huang, et al.
Dalton Transactions (2023) Vol. 52, Iss. 15, pp. 4737-4751
Closed Access | Times Cited: 19
Design of Selective PARP-1 Inhibitors and Antitumor Studies
Yiting Zhang, Xiangqian Li, Fang Liu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 8877-8901
Closed Access | Times Cited: 7
Progress of Bromophenols in Marine Algae from 2011 to 2020: Structure, Bioactivities, and Applications
Hui Dong, Songtao Dong, Poul Erik Hansen, et al.
Marine Drugs (2020) Vol. 18, Iss. 8, pp. 411-411
Open Access | Times Cited: 46
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Xiaopeng Peng, Wanyi Pan, Feng Jiang, et al.
Pharmacological Research (2022) Vol. 186, pp. 106529-106529
Closed Access | Times Cited: 24
Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
Zhimin Zhang, Xinyue Chang, Chixiao Zhang, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2020) Vol. 35, Iss. 1, pp. 1606-1615
Open Access | Times Cited: 35
Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2
Yu Jiang, Lingling Luo, Tong Hu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113898-113898
Closed Access | Times Cited: 30
Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment
Jie Zhang, Yuqi Gao, Zipeng Zhang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16099-16127
Closed Access | Times Cited: 22
Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors
Guoqing Lu, Wenxing Nie, Meixiu Xin, et al.
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114790-114790
Closed Access | Times Cited: 19
An overview of compound properties, multiparameter optimization, and computational drug design methods for PARP-1 inhibitor drugs
Bhakti Umesh Hirlekar, Anila Nuthi, Krishan Dev Singh, et al.
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115300-115300
Closed Access | Times Cited: 11
Advances in Development of Selective Antitumor Inhibitors That Target PARP-1
Fang Liu, Jia‐Shu Chen, Xiangqian Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 24, pp. 16464-16483
Closed Access | Times Cited: 11
Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors
Chao Lin, Chang Liu, Panpan Hu, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107455-107455
Closed Access | Times Cited: 4
Engaging an engineered PARP-2 catalytic domain mutant to solve the complex structures harboring approved drugs for structure analyses
Xiaoyu Wang, Jie Zhou, Bailing Xu
Bioorganic Chemistry (2025), pp. 108471-108471
Closed Access
Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate
Zhenlei Zhang, Ping Yu, Yi Gou, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 23, pp. 10630-10644
Closed Access | Times Cited: 34
Design, synthesis and biological evaluation of homoerythrina alkaloid derivatives bearing a triazole moiety as PARP-1 inhibitors and as potential antitumor drugs
Shuai Li, Xinyang Li, Tingjian Zhang, et al.
Bioorganic Chemistry (2019) Vol. 94, pp. 103385-103385
Closed Access | Times Cited: 32
Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells
Zhangxu He, Jin-Ling Huo, Yunpeng Gong, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112970-112970
Closed Access | Times Cited: 32
Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors
Shuai Li, Xinyang Li, Tingjian Zhang, et al.
Bioorganic Chemistry (2020) Vol. 96, pp. 103575-103575
Closed Access | Times Cited: 28
Page 1 - Next Page

Scroll to top